CDC-RFA-DD-26-0025: Understanding and Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCBDDD notices from 2026.
Centers for Disease Control - NCBDDD offered grants to any type of organization. It expected to make about 11 awards worth $18.0 million in total. Applications closed on June 15, 2026.
From the official notice on Grants.gov, last changed June 3, 2026. Checked November 7, 2026.
- Total funding$18.0 million
- Expected awards11
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 15, 2026 |
|---|---|
| Deadline | June 15, 2026 |
| Archived by Grants.gov | October 1, 2026 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Component A (Autism Data Collection and Dissemination): Applicants must have documented access to individual contact and eligibility data from participants in the Study to Explore Early Development (SEED) phases 1, 2, and/or 3 for all cohorts they propose to include in their recruitment pool to ensure successful completion of the data collection outlined in Component A of the NOFO. Therefore, applicants must either: 1) be the original entities that collected the original SEED data on children 2-5 years of age and their parents/caregivers, and therefore have the information needed to reach these individuals for the Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SPROUT); OR 2) have established collaborative agreements to work with the entities that originally collected contact information from SEED participants (i.e., former SEED recipients) so that they can reach the SEED participants for the data collection as outlined in Component A of the NOFO.Component B (Fragile X Data Collection): Applicants must provide evidence of access to clinic-based samples of children, adolescents, and adults (ages 0-40 years) with fragile X syndrome (FXS) full mutation diagnosis and demonstrate their ability and capacity to collect data on a minimum of 200 unique individuals in this population as outlined in Component B of the NOFO.Component C (Fragile X Data Dissemination): Applicants must demonstrate their ability and capacity to identify and reach populations of people with FXS and their families and communities, as well as healthcare providers, particularly those treating FXS patients, across the United States. Applicants must also demonstrate their ability to generate new communication and continually identify and update resources for the target populations, and well as quantify metrics of impact. Their history of outreach to these populations should include (but may not be limited to) evidence-based educational information, resources, and support.
Is this a realistic fit?
- Most of the program's money (29% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The goal of this NOFO is to gather unique information not collected by other federal programs to gain a better understanding of the resources (e.g., services, supports) and opportunities (e.g., education, employment, housing, social participation) needed to reduce morbidity, mortality, and economic impacts and improve other long-term outcomes for people with autism or Fragile X Syndrome (FXS) across the lifespan. CDC proposes to implement three components in this NOFO.Component A: Survey to Promote Resources and Opportunities for aUtistic Teens and young adults (SPROUT) will utilize cohorts from the Study to Explore Early Development (SEED) Phases 1-3 (collected from 2007-2020), which were case-control studies of autism in children 2-5 years of age. Participants will range from about 10-25 years of age when this NOFO is awarded. SPROUT will be comprised of caregiver and self-report surveys intended to offer unique information on (1) service and support needs and the impact of co-occurring conditions on autistic people and their families and (2) the educational, transitional, social, and/or vocational needs and experiences of autistic adolescents and young adults. Information from these surveys will be used to improve the health and wellbeing of autistic people and their families. These activities are intended to provide data to inform ways to lessen individual, familial, and societal costs associated with autism, reduce morbidity and mortality, and improve health and well-being. Component B: Focus on Advancing Support and Transition with the Fragile X Online Registry With Accessible Research Database (FAST FORWARD) awardees will employ clinic-based enrollment of eligible participants with a recruitment goal of at least 200 eligible persons with FXS per clinic. Similar to SPROUT, awardees will collect data on (1) timing of and barriers to diagnosis, (2) service and support needs and the impact of co-occurring conditions on people with FXS and their families and (3) the educational, transitional, social, and/or vocational needs and experiences of people with FXS and their families. Awardees will participate in project meetings, recruit participants, collect data, record data in a centralized platform, and produce quality public health products. These activities are intended to provide data to inform ways to lessen individual, familial, and societal costs associated with FXS, reduce morbidity and mortality, and improve health and well-being.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before
From fiscal 2021 to 2025, Birth Defects and Developmental Disabilities - Prevention and Surveillance (93.073) awarded $94.9 million across 102 grant awards, an average of $930,644 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 2 | $5.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 4 | $4.9 million |
| University of Texas at Austin | Texas | 2 | $4.2 million |
| Massachusetts Department of Public Health | Massachusetts | 3 | $3.6 million |
| The University of Iowa | Iowa | 3 | $3.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DD-26-0025 still open?
No. It closed on June 15, 2026. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Understanding and Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan?
Centers for Disease Control - NCBDDD accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Understanding and Promoting Resources and Opportunities for People with Autism and Fragile X and their Families Across the Lifespan?
Closed June 15, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $18.0 million in total across about 11 awards.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, University of North Carolina at Chapel Hill, University of Texas at Austin. The program made 102 awards worth $94.9 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)